An HSV-2 nucleoside-modified mRNA genital herpes vaccine containing glycoproteins gC, gD, and gE protects mice against HSV-1 genital lesions and latent infection

HSV-1 causes 50% of first-time genital herpes infections in resource-rich countries and affects 190 million people worldwide. A prophylactic herpes vaccine is needed to protect against genital infections by both HSV-1 and HSV-2. Previously our laboratory developed a trivalent vaccine that targets gl...

Descripción completa

Detalles Bibliográficos
Autores principales: Egan, Kevin P., Hook, Lauren M., Naughton, Alexis, Pardi, Norbert, Awasthi, Sita, Cohen, Gary H., Weissman, Drew, Friedman, Harvey M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7410331/
https://www.ncbi.nlm.nih.gov/pubmed/32716975
http://dx.doi.org/10.1371/journal.ppat.1008795

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7410331/
https://www.ncbi.nlm.nih.gov/pubmed/32716975
http://dx.doi.org/10.1371/journal.ppat.1008795

Ejemplares similares